ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Adjuvant Chemotherapy Unneeded In Children with Low-Risk Disease

March 29, 2013

New DRCCA Board Skeptical Of CIs renewal, Proposal For Cytopathology

September 26, 1980

Postoperative Chemo Doesn’t Improve Survival, Study Finds

March 28, 2008

In Brief: Laird Myers Heads AACE, George Hill President Elect; Cal Tech’s Hood Receives Bertner Award

March 1, 1985

Scatter Radiation from Mammography Presents No Increased Cancer Risk

December 28, 2012

NIES Issue RFA For Studies On Alternative Types Of Cancer Bioassay

October 31, 1980